JPMorgan Chase & Co’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $29.8K | Sell |
3,369
-6,364
| -65% | -$56.3K | ﹤0.01% | 5238 |
|
|
2025
Q1 | $105K | Sell |
9,733
-11,930
| -55% | -$128K | ﹤0.01% | 4714 |
|
|
2024
Q4 | $277K | Buy |
21,663
+16,826
| +348% | +$215K | ﹤0.01% | 4403 |
|
|
2024
Q3 | $134K | Sell |
4,837
-20
| -0.4% | -$552 | ﹤0.01% | 4620 |
|
|
2024
Q2 | $141K | Sell |
4,857
-27,874
| -85% | -$808K | ﹤0.01% | 4446 |
|
|
2024
Q1 | $1.46M | Buy |
32,731
+24,601
| +303% | +$1.1M | ﹤0.01% | 3342 |
|
|
2023
Q4 | $315K | Sell |
8,130
-4,593
| -36% | -$178K | ﹤0.01% | 4157 |
|
|
2023
Q3 | $374K | Buy |
12,723
+954
| +8% | +$28K | ﹤0.01% | 3873 |
|
|
2023
Q2 | $748K | Sell |
11,769
-19,481
| -62% | -$1.24M | ﹤0.01% | 3578 |
|
|
2023
Q1 | $1.48M | Buy |
31,250
+2,643
| +9% | +$125K | ﹤0.01% | 3220 |
|
|
2022
Q4 | $1.99M | Buy |
28,607
+2,607
| +10% | +$181K | ﹤0.01% | 2963 |
|
|
2022
Q3 | $3.81M | Sell |
26,000
-359
| -1% | -$52.6K | ﹤0.01% | 2516 |
|
|
2022
Q2 | $3.44M | Buy |
26,359
+439
| +2% | +$57.2K | ﹤0.01% | 2650 |
|
|
2022
Q1 | $2.62M | Buy |
25,920
+2,702
| +12% | +$273K | ﹤0.01% | 3002 |
|
|
2021
Q4 | $3.59M | Buy |
23,218
+6,114
| +36% | +$946K | ﹤0.01% | 2799 |
|
|
2021
Q3 | $5.06M | Buy |
+17,104
| New | +$5.06M | ﹤0.01% | 2566 |
|